Check-Cap Ltd
Company Profile
- Business description- Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan. 
- Contact- 29 Abba Hushi Avenue 
 Check-Cap Building, P.O. Box 1271
 Isfiya3009000
 ISR- T: +972 48303400 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Diagnostics & Research - Fiscal Year End- 31 December 2025 - Employees- 85 
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,205.00 | 1.70 | -0.02% | 
| CAC 40 | 8,157.29 | 43.59 | -0.53% | 
| DAX 40 | 24,118.89 | 5.32 | -0.02% | 
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% | 
| FTSE 100 | 9,760.06 | 3.92 | 0.04% | 
| HKSE | 26,050.08 | 232.61 | -0.89% | 
| NASDAQ | 23,581.14 | 377.33 | -1.57% | 
| Nikkei 225 | 52,211.69 | 886.08 | 1.73% | 
| NZX 50 Index | 13,544.51 | 85.22 | 0.63% | 
| S&P 500 | 6,822.34 | 68.25 | -0.99% | 
| S&P/ASX 200 | 8,909.10 | 4.10 | -0.05% | 
| SSE Composite Index | 3,961.62 | 25.28 | -0.63% |